{"id":4145,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/lidocaine-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"lidocaine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/lidocaine-txt\/","title":{"rendered":"Lidocaine.txt"},"content":{"rendered":"

Lidocaine <\/h1>\n

CLINICAL USE <\/H3>
\nLocal anaesthetic Ventricular arrhythmias

DOSE IN NORMAL RENAL FUNCTION <\/H3>Local anaesthetic: usually 1 or 2% solutions used, according to patient\u2019s weight and procedureVentricular arrhythmias; 100 mg as a bolus in patients without gross circulatory impairment (50 mg in lighter patients or in severely impaired circulation), followed by an infusion of 4 mg\/min for 30 minutes, 2 mg\/min for 2 hours, then 1 mg\/min or according to local policy

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :288.8<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :66<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.3<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1\u20132\/1.3\u20133

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: increased risk of myocardial depression\n
  • Antibacterials: increased risk of ventricular arrhythmias with quinupristin\/dalfopristin\n
  • Antipsychotics: increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval\n
  • Antivirals: concentration possibly increased by amprenavir, atazanavir, darunavir and lopinavir \u2013 avoid concomitant use with amprenavir and darunavir\n
  • Beta-blockers: increased risk of myocardial depression; increased risk of lidocaine toxicity with propranolol\n
  • Diuretics: effects antagonised by hypokalaemiaDolasetron and tropisetron: increased risk of ventricular arrhythmias \u2013 avoid concomitant use\n
  • Ulcer-healing drugs: concentration increased by cimetidine, increased toxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>IV, SC, topical

    Rate of Administration <\/H4>According to dose

    Comments<\/H4>Usually 1\u20132 mg\/mL in glucose 5% Minimum volume 8\u201320 mg\/mL but watch for extravasation. (UK Critical Care Group, Minimum Infusion Volumes for fluid restricted critically ill patients, 3rd Edition, 2006

    OTHER INFORMATION <\/H4>IV injection lasts for only 15\u201320 minutes
    \n","protected":false},"excerpt":{"rendered":"

    Lidocaine CLINICAL USE Local anaesthetic Ventricular arrhythmias DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4145","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4145"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4145\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}